Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: A Southwest Oncology Group Study.

What Was Tested

The paper reports a study of Suramin and Hydrocortisone, published as a phase 2 clinical trial.

To assess the feasibility of administering a combination of suramin and hydrocortisone in addition to androgen deprivation in a cooperative group setting; to assess the feasibility of treatment with multiple courses of suramin; and to assess progression-free and overall survival in patients with newly diagnosed metastatic prostate cancer who underwent such treatment.

Who Took Part

PubMed indexes the participants as adults, middle-aged adults and older adults, men only.

Patients with newly diagnosed metastatic prostate cancer who had adequate hematologic, hepatic, renal, neurologic, and coagulation parameters were treated by combined androgen deprivation and suramin plus hydrocortisone.

The statistical design was developed on the basis of the feasibility of administering suramin, as judged by the number of patients who developed neurotoxicity of grade 3 or higher or by treatment interruption of 4 weeks or longer due to any persistent suramin-related toxicity.

What Was Measured

PubMed files the paper under topics including Androgens, Antineoplastic Agents, Hormonal, Antineoplastic Combined Chemotherapy Protocols, Disease Progression, Feasibility Studies, Goserelin and Hydrocortisone.

What This Means in Plain Language

This is a phase 2 clinical trial of Suramin and Hydrocortisone.

Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2000 (Journal of clinical oncology : official journal of the American Society of Clinical Oncology), a journal based in United States.

More context: all human trials.